Navigation überspringen
Universitätsbibliothek Heidelberg
Status: Bibliographieeintrag

Verfügbarkeit
Standort: ---
Exemplare: ---
heiBIB
 Online-Ressource
Verfasst von:Blüm, Philipp [VerfasserIn]   i
 Kayser, Sabine [VerfasserIn]   i
Titel:Chimeric antigen receptor (CAR) T-cell therapy in hematologic malignancies
Titelzusatz:clinical implications and limitations
Verf.angabe:Philipp Blüm and Sabine Kayser
E-Jahr:2024
Jahr:22 April 2024
Umfang:29 S.
Illustrationen:Illustrationen
Fussnoten:Gesehen am 15.10.2024
Weitere Titel:Titel des special issue: Innovative Immunotherapies: CAR-T Cell Therapy for Cancers
Titel Quelle:Enthalten in: Cancers
Ort Quelle:Basel : MDPI, 2009
Jahr Quelle:2024
Band/Heft Quelle:16(2024), 8, special issue, Artikel-ID 1599, Seite 1-29
ISSN Quelle:2072-6694
Abstract:Chimeric antigen receptor (CAR) T-cell therapy has become a powerful treatment option in B-cell and plasma cell malignancies, and many patients have benefited from its use. To date, six CAR T-cell products have been approved by the FDA and EMA, and many more are being developed and investigated in clinical trials. The whole field of adoptive cell transfer has experienced an unbelievable development process, and we are now at the edge of a new era of immune therapies that will have its impact beyond hematologic malignancies. Areas of interest are, e.g., solid oncology, autoimmune diseases, infectious diseases, and others. Although much has been achieved so far, there is still a huge effort needed to overcome significant challenges and difficulties. We are witnessing a rapid expansion of knowledge, induced by new biomedical technologies and CAR designs. The era of CAR T-cell therapy has just begun, and new products will widen the therapeutic landscape in the future. This review provides a comprehensive overview of the clinical applications of CAR T-cells, focusing on the approved products and emphasizing their benefits but also indicating limitations and challenges.
DOI:doi:10.3390/cancers16081599
URL:Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.

kostenfrei: Volltext: https://doi.org/10.3390/cancers16081599
 kostenfrei: Volltext: https://www.mdpi.com/2072-6694/16/8/1599
 DOI: https://doi.org/10.3390/cancers16081599
Datenträger:Online-Ressource
Sprache:eng
Sach-SW:axicabtagene ciloleucel
 brexucabtagene autoleucel
 CAR T-cells
 chimeric antigen receptor T-cells
 ciltacabtagene autoleucel
 cytokine release syndrome
 idecabtagene vicleucel
 immune effector cell-associated neurotoxicity syndrome
 lisocabtagene maraleucel
 tisagenlecleucel
K10plus-PPN:1905723857
Verknüpfungen:→ Zeitschrift

Permanenter Link auf diesen Titel (bookmarkfähig):  https://katalog.ub.uni-heidelberg.de/titel/69262559   QR-Code
zum Seitenanfang